Fabry Disease
Fabry disease is an X-linked lysosomal storage disorder caused by GLA gene mutations leading to alpha-galactosidase A deficiency. Accumulation of globotriaosylceramide (Gb3) causes neuropathic pain, angiokeratomas, corneal verticillata, cardiomyopathy, arrhythmias, kidney failure, and stroke risk.
Symptoms
- Neuropathic pain crises (acroparesthesias), burning hands/feet
- Heat intolerance, hypohidrosis, GI discomfort
- Angiokeratomas (dark red skin lesions), corneal verticillata (whorl pattern)
- Kidney dysfunction (proteinuria, reduced eGFR), hypertension
- Cardiac hypertrophy, fibrosis, arrhythmias
- Cerebrovascular events (TIA/stroke)
- Fatigue, tinnitus, hearing loss
Diagnosis
- Alpha-Gal A enzyme activity (low in males; females may have normal levels)
- GLA gene sequencing for confirmation and family screening
- Plasma lyso-Gb3 biomarker for disease burden/monitoring
- Baseline cardiac MRI, echocardiogram, renal function tests, brain MRI if indicated
Treatment Options
Enzyme Replacement Therapy (ERT)
- Agalsidase beta (IV q2 weeks) and agalsidase alfa (available in some regions)
- Reduces lyso-Gb3 levels, improves pain, slows organ damage
- Infusion reactions possible; premedication and monitoring required
Chaperone Therapy
- Migalastat (oral) for amenable mutations to stabilize residual enzyme
- Requires genetic testing to determine suitability
Supportive Care
- Pain management (gabapentinoids, duloxetine)
- ACE inhibitors/ARBs for kidney protection
- Antiplatelet therapy if cerebrovascular risk
- CRT/ICD for arrhythmias, cardiac fibrosis monitoring
- Hemodialysis/transplant for ESRD
Living with Fabry
- Track infusions or oral therapy adherence, lyso-Gb3, renal labs, imaging, pain episodes, cardiac evaluations, and neurologic symptoms
- Maintain cardiovascular fitness, hydration, temperature regulation strategies
- Psychosocial support for chronic pain/fatigue; genetic counseling for family planning
Complications
- Progressive nephropathy requiring dialysis/transplant
- Cardiomyopathy, arrhythmias, heart failure
- Stroke, white matter lesions
- Hearing loss, tinnitus
- Depression/anxiety due to chronic pain
Research & Future Directions
Gene therapy (AAV, lentiviral, lipid nanoparticle mRNA) aims to provide sustained enzyme production. Substrate reduction, novel chaperones, and gene editing are under evaluation.
Experimental & Emerging Treatments
- Gene Therapy (4D-310, FLT190) delivering alpha-Gal A to liver/cardiac tissue.
- mRNA Therapy: Lipid nanoparticle injections encoding alpha-Gal A.
- Substrate Reduction: Oral agents targeting Gb3 synthesis (lucerastat) in trials.
- Digital Biomarkers: Wearables monitoring HRV and temperature sensitivity to quantify symptom burden.
Track Fabry with Diagnoza.care
Protect Heart, Kidneys & Nerves – Log infusion dates, migalastat dosing, biomarkers, renal labs, urine protein, cardiac imaging, neurologic exams, pain crises, and specialist visits; capture side effects; and let the AI companion remind you of surveillance for kidneys, heart, and brain.
Medical Disclaimer: Informational only. Work with your metabolic/cardiology/nephrology team for therapy selection, mutation-specific guidance, and lifelong monitoring.
Sources: National Fabry Disease Foundation, European Fabry Working Group, American College of Medical Genetics